Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2008.022 | Oncogenic Dependency on Receptor Tyrosine Kinase (RTK): Implication for Molecular Targeting in Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2010.081 | Oncogenic Regulation of TIGAR by STAT3: A Mechanistic Study | Ph.D. LUI Vivian Wai Yan |
| 2020.007 | One Health approach to Track and Target Antimicrobial Resistance (TnT-AMR) |
Prof. IP Margaret 葉碧瑤 |
| 2011.405 | One year course and risk factors of personality change after stroke | Prof Tang Wai Kwong |
| 2024.132 | One-step Rehydration Thawing Method in Frozen Embryo Transfer: A pragmatic randomized controlled clinical trial (ORT-FET-RCT) | Dr. CHAN David Yiu Leung |
| 2023.387 | One-year course and predictors of personality change after stroke. |
Prof. TANG Wai Kwong Wai Kwong Tang |
| 2012.307 | One-year outcome of the Shatin Personalized Care Programme for patients with severe mental illness in comparison with the Community Psychiatric Nurse Service in the New Territory East Cluster | Dr. Fong Man Yee |
| 2013.205 | One-year outcome study of a chronic pain management programme in Hong Kong | Dr Chu Ming Chi |
| 2016.179 | One-Year Outcomes of Presbyopic Correction Using Monocular Bi-aspheric Ablation Profile (PresbyMAX) in Hyperopic Eyes |
Dr. CHAN Tommy 陳頌恩 |
| 2020.538 | Online AR Training Platform for the Elderly and Persons with Chronic Diseases at Home |
Prof. TONG Kai Yu 湯啟宇 |
| 2021.268 | Online integrated mindfulness-meaning programme for depression and anxiety during COVID-19: A pilot randomized controlled trial |
Prof. ZHANG Daisy 張德杏 |
| 2022.183 | Online Mindfulness-based Intervention to Enhance Bracing Compliance for Adolescent Idiopathic Scoliosis (AIS) – A Pilot Randomized Single-blinded Controlled Trial |
Prof. LAM Tsz Ping 林子平 |
| 2014.032 | Online Modulation of Auditory Brainstem Responses to Speech | Prof. WONG Patrick Chun Man |
| 2020.486 | Online multicomponent health intervention to support children with special education needs (SEN) and their families during COVID-19 pandemic |
Dr. LEE Eric 李錦培 |
| 2022.188 | Online Temporal Processing Assessment and Training for Children |
Prof. CHAN Agnes Sui Yin 陳瑞燕 |
| 2006.270 | ONTARGET and TRANSCEND Study (Protocol No. 502.373) | CHAN Chi Kin Hamish |
| 2024.089 | Open and closed platform robotic-assisted versus conventional total knee arthroplasty: a randomised controlled trial | Prof. ONG Michael Tim Yun |
| 2015.053 | Open globe injuries in geriatric nursing home residents | Dr. FONG Yoly Yeuk Ying |
| 2002.444 | Open Label Extension and Long Term Safety Study of Tolterodine PR Capsules in Children 5 to 11 Years of Age with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability | Prof. Yeung Chung Kwong |
| 2005.445 | Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of An Iron Maintenance Dosing Strategy Utilizing Intravenous VIT-45 in the Treatment of Anemia in Non-Dialysis Dependent (NDD) Chronic Kidney Disease (CKD) | Prof. Szeto Cheuk Chun |
| 2003.259 | Open Label Single Arm Phase 2 Study of ALIMTA in Patients with Advanced Non-Small Cell Lung Cancer Who have Prior Chemotherapy | Prof. Mok Tony |
| 2017.169 | Open label single arm study for NEPA [oral fixed-dose combination of 300 mg netupitant and 0.50 mg palonosetron] in Hong Kong oncology patients receiving (neo)-adjuvant chemotherapy treatment consists of adriamycin and cyclophosphamide for breast cancer. | Prof. YEO Winnie |
| 2006.307 | Open Label Study of bevacizumab (AVASTIN_) in Combination with Platinum Containing Chemotherapy as First Line Treatment of Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (SAIL-Safety of Avastin In Lung) | Prof. Mok Tony |
| 2002.500 | Open Label Treatment Compassionate Access Programme to Provide Adefovir Dipivoxil and Lamivudine to Patients with Chronic Hepatitis B Infection who are Participating in or Have Completed, As Appropriate, one of the Following GlaxoSmithKline or Gilead Sciences Inc. Clinical Trial : NUC20917, NUC20912, NUC4006, NUC40021 and Study 435 | Prof. Sung Jao Yiu Joseph |
| 2012.351 | Open liver resection with or without vascular inflow occlusion for hepatocellular carcinoma: a randomized controlled trial | Dr Lee Kit-fai |
| 2008.037 | Open Liver Resection with or without Vascular Inflow Occlusion: A Randomised Control Trial | Dr Lee Kit-fai |
| 2008.366 | Open-Label Extension Study of 23 mg Donepezil SR in Patients with Moderate to Severe Alzheimer | Prof. Mok C.T. Vincent |
| 2017.257 | Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2006.368 | Open-Label Study of Bevacizumab (Avastin_) Plus Taxane Monotherapy or in Combination for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer ATHENA (Avastin THErapy for advaNced bresAst cancer) | Dr. Ho Wing Ming |
| 2016.597 | Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2016.688 | Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) Including Those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2015.087 | Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas (Part B) | Dr. WONG Raymond Siu Ming |
| 2004.314 | Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5-FU/FA Plus Irinotecan Plus Cetuximab Versus 5-FU/FA Plus Irinotecan as First-Line Treatment for Epidermal Growth Factor Receptor | Prof. Chan Tak Cheung Anthony |
| 2021.135 | Operative Mortality After Triple Valve Surgery: Prognostic Value of Simplified MELD-Na | Dr. LIM Kevin |
| 2019.618 | Opioid analgesics during and following radiotherapy treatment of head and neck tumours | Dr. CHAN Jason Ying Kuen |
| 2015.718 | Opt-out HIV testing in out-patient setting | Prof. TAM Greta Chun Huen |
| 2004.081 | Optical Brian Imaging of Incidental and Intentional Memory Retrieval | PENNEY Trevor |
| 2021.505 | Optical coherence tomography (OCT) for lung imaging |
Dr. YUAN Wu 袁武 |
| 2021.273 | Optical Coherence Tomography and Optical Coherence Tomography Angiography features in Cytomegalovirus Retinitis | Dr. WONG Po Yin |
| 2017.358 | Optical Coherence Tomography evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris | Prof. YAN Bryan Ping Yen |
| 2015.297 | Optical Coherence Tomography evaluation of Very Early eNdothelialization after Dual Therapy Drug-eluting Stent with EPC CaptURE (OCT-VENTURE) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.291 | Optimal Bioabsorbable Vascular Scaffold Technique for Complex Bifurcation Lesions |
Dr. YAN Bryan Ping Yen 甄秉言 |
| 2024.134 | Optimal Dosage of Atropine and Red Light Combination Therapy for Myopia Treatment (LAMP-4) Study | Dr. YAM Jason Cheuk Sing |
| 2019.245 | Optimal proximal interphalangeal joint position for treatment of mallet finger: a cadaveric biomechanical study |
Dr. MAK Suk Ying 麥淑楹 |
| 2020.224 | Optimal Strategy for the Monitoring of Dialysis Adequacy in Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2005.442 | Optimal Time of Laparoscopic Cholecystectomy After Endoscopic Clearance of Endoscopic Bile Duct Stone Removal in Acute Cholangitis | Prof. NG Kwok Wai |
| 2017.240 | Optimal timing of umbilical cord clamping for term babies with natural birth – a randomised open-labelled trial |
Prof. TAM Wing Hung 譚永雄 |
| 2004.302 | Optimal Ventricular Resynchronization and Nt-proBNP in Heart Failure Therapy | Prof. Yu Cheuk Man |
| 2005.121 | Optimisation of Antihypertensive Therapies: Application of Pharmacogenomic and Biochemical Technologies ptimisation of Antihypertensive Therapies: Application of Pharmacogenomic and Biochemical Technologies | Prof. Brian Tomlinson |
| 2009.217 | Optimise CRT | Professor Yu Cheuk-Man |
Page 171 of 254.